Observational studyNeurology(R) neuroimmunology & neuroinflammation2025
Extracellular Vesicles as Novel Biomarkers for Tumor Association in Intermediate-Risk Paraneoplastic Neurologic Syndromes.
Gabriel Torres Iglesias, Alba Chavarría-Miranda, MariPaz López-Molina, Carlos Del Fresno, Pablo Mata-Martínez, Pilar Nozal, Juan Luis Chico-Garcia, Mireya Fernández-Fournier, Laura Lacruz Ballester, Darío Sanchez and 8 more
Abstract readObservational StudyMulticenter Study
In one paragraphObservational study in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Gabriel Torres IglesiasNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0001-6479-731X Alba Chavarría-MirandaDepartment of Neurology, Hospital Clinic of Valladolid, Valladolid, Spain.
MariPaz López-MolinaNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0002-9171-2606 Carlos Del FresnoImmunomodulation Laboratory, Innate Immune Response Group, Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.
Pablo Mata-MartínezImmunomodulation Laboratory, Innate Immune Response Group, Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0009-0005-0929-3908 Pilar NozalComplement Research Group, Immunology Service, Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Spain.
Juan Luis Chico-GarciaDepartment of Neurology, Ramón y Cajal University Hospital, IRYCIS Research Institute, Madrid, Spain.
Mireya Fernández-FournierNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.
Laura Lacruz BallesterNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.
Darío SanchezDepartment of Oncology, Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.
Susana BravoProteomic Unit, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.ORCID 0000-0001-7615-3079 Inmaculada PuertasNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0002-9567-1274 Elisa YorkDepartment of Neurology, Hospital Clinic of Valladolid, Valladolid, Spain.
Exuperio Díez-TejedorNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0003-2295-1707 María Gutiérrez-FernándezNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0002-6615-4729 Laura Otero-OrtegaNeurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Institute for Health Research-IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0001-8765-6341 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
BACKGROUND AND
objectivesParaneoplastic neurologic syndromes (PNS) are cancer-related neurologic disorders caused by an autoimmune response targeting both the tumor and the nervous system. Identifying new biomarkers for early cancer detection could improve treatment outcomes. Tumor-derived cells release extracellular vesicles (EVs) carrying tumor-specific molecular signatures, which can help distinguish patients with cancer even in early stages. The aim of this study was to assess the potential of EVs as biomarkers to enhance cancer detection in patients with PNS.
methodsThis observational and multicenter study included 27 patients with tumor-associated PNS, 26 with suspected PNS without a tumor, 35 with cancer, and 32 healthy controls. Subsequently, among the patients with PNS, individuals were subclassified according to the PNS-Care Score as definite, probable, possible, and non-PNS. Total EVs were isolated from blood by precipitation and from B cells, T cells, and neurons by immunoisolation. To identify a biomarker for diagnostic refinement and clinical stratification, EV levels, size, and protein content were compared across study groups. To find a tumor biomarker in intermediate-risk cases, the possible association between EV protein content and cancer detection in intermediate-risk syndromes was analyzed.
resultsPatients with tumor-associated PNS showed significantly higher circulating EV levels compared with those with suspected PNS without evidence of a tumor ( DISCUSSION: EVs may act as tumor biomarkers in patients with PNS, even in intermediate-risk cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that higher circulating blood levels of EVs can distinguish between tumor-associated PNS from suspected PNS without tumor.
Indexed as
Biomarkers, TumorExtracellular VesiclesParaneoplastic Syndromes, Nervous SystemAdultAgedFemaleHumansMaleMiddle AgedBiomarkers, Tumor
Identifiers
PMID41071973
PMCPMC12516854
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390